7[1] Weidmann P,Ferrier C,Saxenhofer H,et al.Serum lipoproteins during treatment with antihypertensive drugs[J].Drugs，1988，35 Suppl 6:118
8[2] Leren P.Lipid effects of antihypertensive drugs[J].Clin Exp Hypertens A，1990，12(5):761
9[3] McTavish D,Campoi-Richards D,Sorkin EM.Carvedilol,a review of its pharmacodynamic and pharmacokinetic properties,and therapeutic efficacy[J].Drugs,1993，45(2):232
10[4] Goto-Y,Tamachi-H,Fusegawa-Y,Nakaya-N,et al.Effects of carvedilol on serum lipids in patients with essential hypertension[J].J Cardiovasc Pharmacol，1991，18(Suppl 4):S45
2Del Sindaco D, Pulignano G, et al. Safety and ettqcacy of carvedilol in veryelderly diabetic patients with heart failure[J]. J Clll - ovasc Ned (Hagerstown) ,2007,8(9) : 675 -682.
3Capomolla S, Febo O, Gnemmi M, et al. - blockade therapy in chronic heart failure diastolic function and mitral Regurgitation improvement by carvedilol[J]. Am Heart J, 2000, 139 (4) : 596.
4Foody J M, Farrell M H, Krumholz H M. Beta-blocker therapy in heart failure: scientific review[J]. JAMA, 2002, 287: 883.
5Packer H. Bets-adrenergic blocksde in chronic heart failure:principles, progress, andpractice[J].Prog Cardiovasc Dis, 1999, 41 (Suppl 1):39.
6Bristow MR. Mechanism of action of beta-blocking agent in heart failure[J].Am J Cardiol,2001,80:26.
